



AJJ MEDTECH HOLDINGS LIMITED
(Company Registration No. 198403368H)
(Incorporated in the Republic of Singapore)

RESEARCH AND TECHNOLOGY PLATFORM DEVELOPMENT UPDATE RELATING TO THE RR-ETHICS™ / HERI ETHICAL READINESS INDEX FRAMEWORK FOR THE RESPONSIBLE AND GOVERNED DEPLOYMENT OF EMBODIED AI HUMANOID ELDERCARE ROBOTS

The Board of Directors (the “Board”) of AJJ Medtech Holdings Limited (the “Company”, and together with its subsidiaries, the “Group”) wishes to announce that the Group’s Research Division has prepared a company-led research and technical paper relating to the Group’s healthcare technology platform development initiatives, entitled:

“RR-Ethics™: A Human-Centred Ethical Readiness Index for Responsible Deployment of Embodied AI Humanoid Eldercare Robotics — A Systems-Oriented HERI Framework for Legal Accountability, Safety Boundaries, Public Health Protection and Institutional Deployment Governance.”

The technical paper relates to the Group’s continuing work in embodied AI humanoid eldercare robotics, ethical-readiness assessment, legal accountability, safety-boundary governance, public health protection, institutional deployment governance, auditability, data governance and responsible institutional deployment assessment.

The technical paper is intended to be made available as a company-led DOI-registered frontier systems technical paper and published on the Group’s corporate website Research page, for the purpose of establishing a public, traceable, citable and reviewable research record. The relevant DOI and website link are as follows:

Document Type: Company-led DOI-registered frontier systems technical paper
Status: Public research version; not independently peer-reviewed
DOI: 10.5281/zenodo.21002067, <https://zenodo.org/records/21002067>
Website: <https://www.ajjmedtech.com.sg/publication-3>

The Company will also publish a public-facing Q&A explanatory note on RR-Ethics™ / HERI on its corporate website to facilitate public understanding.

1. Author and ESG-Related Research Contribution

The technical paper identifies Ms Alice Zhao Xin, Dr Tan Wei Jie and Ms Shen Tian as equal first authors. Ms Alice Zhao Xin, formerly the Group Chief Executive Officer and currently a Strategic Advisor to the Group, continues to lead and participate in the Group’s healthcare technology platform development, research coordination, industry-academic collaboration and strategic knowledge-transfer initiatives. Dr Tan Wei Jie is the current Group Chief Executive Officer. Ms Shen Tian has been appointed as a Research Expert / Expert Consultant of AJJ Research to provide professional support and advisory input in relation to the Group’s research work on eldercare robotics, embodied artificial intelligence, healthcare management, academic papers and technical white papers.

The contributing authors also include Wentao Zhao, Qiang Huang, Hon Hsiang Ong, Wenqun Guo, Tingting Shen, Chunqiu Yan and Jian Zhang. Based on the author contributions stated in the technical paper, the work was jointly contributed to by AJJ Healthcare Management Pte. Ltd., relevant Group members and the

Group's external technology collaboration partner, Hangzhou Huaxi Intelligent Technology Co. Ltd. Such participation reflects the Group's continued collaboration in healthcare technology platform development, responsible deployment, evidence control, talent development, cross-team research capability building, leadership continuity and knowledge transfer under its ESG framework.

2. Background

The Company believes that, in line with the Group's 2026 Vision and Execution Plan and its AJJ × Huaxi Intelligent Technology collaboration relating to AI-enabled humanoid eldercare robotics, responsible deployment should not be assessed solely by product functionality, mobility, interaction capability, monitoring support or workflow-assistance functions. As previously disclosed by the Group, the HIT-1 platform forms part of the Group's multifunctional embodied AI humanoid eldercare robotics initiative, which is intended to support selected institutional care environments through human-supervised workflow enhancement, healthcare-related support functions and structured deployment governance.

As embodied AI humanoid eldercare robots enter institutional care environments, their responsible deployment requires structured ethical-readiness assessment covering human oversight, dignity protection, consent and autonomy safeguards, privacy and data governance, safety boundaries, accountability, auditability, public health protection, workplace safety, caregiver fairness and post-deployment monitoring. In this context, RR-Ethics™ / HERI is designed as an ethical-readiness and institutional decision-support framework for assessing whether an embodied AI humanoid eldercare robot may be considered supportable for controlled institutional deployment review under defined operating conditions, evidence boundaries, human-supervision requirements and institutional safeguards.

3. Overview of HERI

HERI Version 1.0 comprises ten assessment dimensions: dignity and personhood protection; consent, autonomy and proxy safeguards; privacy and data proportionality; safety and medical-boundary control; human oversight and override; legal accountability and responsibility chain; auditability and traceability; public health and workplace safety; emotional dependency and substitution control; and caregiver justice, training and workflow fairness.

The framework is designed to translate established care-robot ethics, healthcare AI governance and AI robot accountability principles into a structured, evidence-linked ethical-readiness assessment architecture for embodied AI humanoid eldercare robotics. HERI is intended to support ethical-readiness discussion, institutional deployment review, governance and oversight assessment, deployment-risk identification, documentation review, evidence evaluation and future research refinement.

4. First-Definition-Type and Early Integrated Framework Positioning

Based on the Group's public-source, academic, policy, standards, cross-language and negative-verification searches conducted to date, including the Group's internal **RR-Ethics™ / HERI prior-art, public-source and literature search review**, the Group has not identified a highly identical public integrated ethical-readiness index framework to RR-Ethics™ / HERI within the reviewed scope. Subject to the limitations and evidence boundaries set out in the supporting review materials, RR-Ethics™ / HERI may therefore be described as a **first-definition-type and among the earliest identified integrated ethical-readiness assessment frameworks** for the responsible deployment of embodied AI humanoid eldercare robots.

The Group further considers that RR-Ethics™ / HERI may exhibit **certain world-first-characteristic features**, particularly in combining a **structured ethical-readiness index, human-centred care-robot ethics, legal accountability, safety-boundary control, public health and workplace safety considerations, evidence-linked assessment logic and institutional deployment governance** for embodied AI humanoid eldercare robots. This positioning describes the Group's research contribution and framework-setting direction, and should not be interpreted as a legally, regulatorily or academically conclusive claim of absolute global uniqueness, independent third-party validation, regulatory recognition or formal academic endorsement.

5. Important Interpretation Boundaries

The Board wishes to emphasise that RR-Ethics™ / HERI and the related technical paper are released for research, technical disclosure, public reference and framework-development purposes only. They do not constitute independent peer-reviewed journal publication, ethics approval, IRB approval, DSRB approval, institutional approval, regulatory approval, medical-device certification, product clearance, clinical validation, legal advice, compliance clearance, government endorsement, institutional endorsement, third-party validation, commercial valuation, sales forecast, investment recommendation, profit forecast or universal deployment permission.

Any future empirical validation, clinical evaluation, resident-level study, identifiable personal-data use, institutional deployment, regulated medical-device assessment or site-specific implementation should be subject to appropriate ethical, legal, institutional, data-protection, regulatory and professional review, as applicable.

6. Public Research Status and Evidence Boundary

The RR-Ethics™ / HERI technical paper is a company-led research and technical framework document intended to support transparent research disclosure, public reference, ethical-readiness discussion, governance discussion and subsequent scholarly development. It is not a peer-reviewed journal article as at the date of this announcement, and any future journal submission, peer review or academic publication will remain subject to the relevant journal's editorial policies, peer-review process and publication decisions.

The technical paper includes framework-development materials and evidence-related interpretation developed within a bounded pioneer-developer context. Supporting evidence materials are anonymised, institutionally controlled and retained internally for framework-development, academic review, qualified review, governance reference and evidence-control purposes. No supplementary evidence files are publicly released with the company-led technical disclosure version. Such materials and any illustrative framework assessment should be interpreted cautiously and should not be read as independent third-party validation, regulatory approval, clinical validation, medical-device certification, product certification, universal safety proof, market assurance or final deployment approval.

7. Strategic Relevance to the Group

The Company believes that RR-Ethics™ / HERI may support the Group's longer-term healthcare technology platform development by providing a structured ethical-readiness language for AI-enabled humanoid eldercare robots, supporting engagement with institutions, regulators, healthcare operators, eldercare service providers, academic parties, technology partners and other stakeholders, and strengthening the Group's positioning in responsible AI, human oversight, data governance, auditability, safety-boundary control, public health protection and responsible institutional deployment.

The Company further believes that RR-Ethics™ / HERI complements the broader research roadmap currently being advanced by the Group, **including RR-Care™, RR-Gov™, RR-Ethics™, HVCL_{2.3} and research relating to the medical applications of humanoid eldercare robots**, by providing an ethical-readiness reference basis for institutional deployment review, responsible implementation planning, evidence-bound interpretation and future scholarly development. Such research work may enhance the explainability, reviewability and external communication basis of the Group's healthcare technology platform, and provide a citable, traceable and scalable research foundation for more systematic engagement with healthcare and eldercare institutions, technology partners, academic parties, government-related stakeholders and potential investors.

8. Important Cautionary Statement

Shareholders and potential investors should note that this announcement and the RR-Ethics™ / HERI technical paper are intended as a research and technology platform development update only. They do not constitute or imply regulatory approval, clinical validation, ethics approval, medical-device or product

certification, government or institutional endorsement, commercial contract, sales or profit forecast, investment recommendation, product deployment readiness confirmation, or any assurance of future revenue, profitability, commercial adoption or financial performance.

RR-Ethics™ / HERI is a research and ethical-readiness assessment framework developed for structured discussion, institutional review, evidence-bounded interpretation and future scholarly development. Any future deployment, institutional adoption, regulatory interaction, commercial arrangement, clinical assessment or financial contribution will remain subject to separate evaluation, applicable laws and regulations, institutional requirements, ethical review, regulatory processes, operational conditions, data-governance requirements and market conditions.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company and should consult their professional advisers if in doubt.

BY ORDER OF THE BOARD

Dr Tan Wei Jie

Chief Executive Officer and Executive Director

Date: 08th July 2026

This document has been reviewed by the Company's sponsor, Evolve Capital Advisory Private Limited (the “Sponsor”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “Exchange”) and the Exchange assumes no responsibility for the contents of this document, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Mr. Jerry Chua (Tel: (65) 6241 6626), at 160 Robinson Road, #20-01/02, SBF Centre, Singapore 068914.